INVO Bioscience Inc (OTCQB: IVOB), a US-based medical device company, has received approval from Institutional Review Board for a clinical trial studying a modified INVOcell system for use in pregnancy and fertilisation, it was reported on Wednesday.

The study intends to evaluate the efficacy, comfort and retention of the INVOcell with the retention device, in a bid to display superiority following five-day vaginal incubation as against the present three-day vaginal incubation indication.

The trial is a single arm, multicentre, open label trial at three clinical centres in the United States with each centre enrolling 60 patients between the ages of 18 and 37 years old. Each centre is to conduct the processes of ovarian stimulation, egg retrieval and embryo transfer. The company has started enrolling patients at each site.